Neuro-oncology and supportive care: the role of the neurologist

2022 ◽  
Author(s):  
Natalie E. Stec ◽  
Tobias Walbert
Keyword(s):  
Supportive Care

Granulocyte Transfusions

PEDIATRICS ◽  
1988 ◽  
Vol 81 (6) ◽  
pp. 915-915
Author(s):  
MITCHELL S. CAIRO
Keyword(s):  
Supportive Care ◽  
Preterm Infants ◽  
Clinical Setting ◽  
Neonatal Sepsis ◽  
Statistical Significance ◽  
Buffy Coat ◽  
Granulocyte Transfusion

In Reply.— The comments raised by Baley et al are well taken and bring up one of the most important variables in the role of granulocyte transfusion in neonatal sepsis. Most of the studies to date have involved small numbers of patients in single institutions. This has prevented us from accumulating a large enough population of patients to adequately assess the role of either buffy coat transfusions or leukapheresed transfusions in this clinical setting. My comments in the commentary suggested that, with only eight patients in a group of preterm infants with presumed sepsis and only five patients with presumed sepsis with birth weights greater than 1,500 g, the numbers are essentially too small to determine any statistical significance between the role of buffy coat transfusions or supportive care.

scholarly journals Complex prescribing in chronic kidney disease: role of the renal pharmacist in kidney supportive care in uncovering hydralazine‐related lupus

2019 ◽  
Vol 49 (4) ◽  
pp. 364-367 ◽  
Author(s):  
Carla E. Scuderi ◽  
Ilse R. Berquier ◽  
Louise A. Purtell ◽  
Ann J. Bonner ◽  
Carol M. Douglas ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Supportive Care

scholarly journals Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids

Breathe ◽  
2020 ◽  
Vol 16 (3) ◽  
pp. 200086
Author(s):  
Christopher J. Brereton ◽  
Helen E. Jo
Keyword(s):  
Disease Management ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Supportive Care ◽  
Disease Process ◽  
Evidence Base ◽  
Fatal Complication ◽  
Acute Exacerbations ◽  
International Awareness

An acute exacerbation of idiopathic pulmonary fibrosis (AEIPF) is a potentially fatal complication of an already debilitating disease. Management is currently centred on delivering excellent supportive care and identifying reversible triggers. Despite growing international awareness and collaboration, no effective therapies have been identified. Corticosteroids are often the mainstay of treatment; however, the evidence base for their use is poor. Here, we review our current understanding of the disease process and how to manage it, with a focus on the role of corticosteroid therapy.

scholarly journals Burden and happiness in head and neck cancer carers: the role of supportive care needs

2016 ◽  
Vol 24 (10) ◽  
pp. 4283-4291 ◽  
Author(s):  
Paul Hanly ◽  
Rebecca Maguire ◽  
Myles Balfe ◽  
Philip Hyland ◽  
Aileen Timmons ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Supportive Care ◽  
Head And Neck ◽  
Neck Cancer ◽  
Supportive Care Needs ◽  
Care Needs

Choice of chemotherapy (CT) for advanced/metastatic lung carcinoma, WHO types I - III - IV (NSCLC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17132-17132
Author(s):  
R. Bollina ◽  
G. Beretta ◽  
P. Belloni ◽  
D. Toniolo ◽  
C. Cozzi ◽  
...  
Keyword(s):  
Supportive Care ◽  
Prospective Study ◽  
Advanced Nsclc ◽  
Subjective Response ◽  
Second Line ◽  
Short Term ◽  
Metastatic Lung ◽  
Metastatic Lung Carcinoma ◽  
The Impact

17132 For NSCLC optimal CT has not been established so far, while many equivalent moderately active schemes are used. The present 40-month study randomized 71 consecutively accrued patients (pts) with parametrable disease between platinum(P)-based three-weekly combinations and non-P monoCT (weekly gemcitabine, vinorelbine or taxane). 68 evaluable pts characteristic were well balanced between treatments: median age 67 years (r. 40–82y), median P Status < 2 WHO scale (r. 0–2),male predominant 82.3%, ratio of IIIb/IV = 1.34 and squamous/non squamous histotype = 1.19, pathologies 26% (only mild to moderate, not contraindicating CT). Objective/subjective response (RECIST/MILAN criteria, JNCI 92:180; P.ASCO 19:642a) after poliCT (PCT) or monoCT (MCT) are reported in the descriptive table . Tolerance was good for both treatment, MCT resulting less deeply toxic and more easily accepted by the majority of pts. This study is still ongoing to achieve the total pts accrual in order to explore statistical significant in the principal determinant subgroup, to determine the subjective response to CT, and to confirm a possible difference in survival. The role of a programmed second line CT vs supportive care alone, and the impact of adding new biomolecular therapies (combined with CT) are the short-term challenges of the second part of this prospective study for advanced NSCLC. [Table: see text] No significant financial relationships to disclose.

Advanced cancer patients' (CP) attitudes and perceptions regarding reasons for outpatient supportive care (SC) referral at a comprehensive cancer center: A randomized controlled study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24135-e24135
Author(s):  
Angelique Wong ◽  
Frank V. Fossella ◽  
George R. Simon ◽  
Rama Maddi ◽  
Zhanni Lu ◽  
...  
Keyword(s):  
Supportive Care ◽  
Cancer Care ◽  
Comprehensive Cancer Center ◽  
Controlled Study ◽  
Cancer Center ◽  
Cancer Type ◽  
Attitudes And Perceptions ◽  
Outpatient Supportive Care

e24135 Background: Current ASCO guidelines propose early access to SC in all CP to improve quality of care, quality of life, and symptoms. Very few studies have evaluated patients’ perceived criteria for referral to outpatient SC and perceptions of patients who are referred early in their disease trajectory. Methods: In this study we evaluated CP attitudes and perceptions regarding the role of and access to outpatient Supportive Care clinic (SCC) at a comprehensive cancer center. CP with life expectancy of greater than 6 months (as determined by the oncologist) and who are newly registered at MD Anderson Cancer Center were randomized to either obtain an educational brochure that explained the role of the SCC or no brochure. Both groups then completed a survey regarding the role and access to of outpatient SCC. After completion of the survey, patients were asked if they would like to be seen by the SC team. If so, they were scheduled by their oncologist for a SC consult. Results: 288 patients were evaluable: median age was 63, 43% were female, 84% were Caucasian, and the most common cancer type was lung cancer (39%). Median survival was 15 months. Patients who received a brochure reported more understanding of the role of SC vs those who did not receive a brochure (63% vs 37%, p = 0.04). Both groups felt that SC could help to address physical (47% vs 54%) and psychosocial (50% vs 50%) symptoms. Both groups felt SC could help to address questions regarding prognosis (50% vs 50%) and future care (53% vs 47%). Both groups did not feel that time (50% vs 50%) nor financial concerns (49% vs 51%) would be barriers to access SC. Both groups did not feel that receiving SC would impede their cancer care (60% vs 40%) nor change their oncologists’ perspective of them (25% vs 75%). Both groups felt they could receive SC and cancer care simultaneously (50% vs 50%). Approximately half of the patients in both groups perceived it was not too early for a referral to SC. There were no statistical differences in these groups for these findings. Conclusions: Patients who received a brochure had a better understanding of the role of SC. A very significant proportion in both groups had limited awareness of the value of SC. Oncologist driven referral and education of SC may facilitate better understanding of the value of SC. Further studies are needed.

Sign in / Sign up

Export Citation Format

Share Document